Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols
Cost and access are actual concerns
External resources New England Journal of Medicine: Retatrutide Phase 2 Trial Results FDA Drug Safety and Availability Information For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, personalized protocol tools, and a community of thousands who have navigated these exact dosing decisions
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway
In controlled clinical trials, daily intakes of aged garlic extract at doses between 1.2 g-2.4 g (containing 1.2 to 2.4 mg of S-allyl-L-cysteine) consistently resulted in reductions in SBP by 9 mm Hg-10 mm Hg and reductions in DBP by 4 mm Hg-8 mm Hg in a majority of patients with uncontrolled hypertension (110, 143)
(PubMed) Chiavarini M, Minelli L, Fabiani R
